Can I Take Lion's Mane with Tresiba (Insulin Degludec)?

What Is Tresiba and How Does It Work?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin approved by the FDA in September 2015 for adults with type 1 and type 2 diabetes, and later for pediatric patients aged one year and older [1]. Its half-life exceeds 25 hours, and its duration of action extends beyond 42 hours, which is meaningfully longer than insulin glargine U-300 [2].

Mechanism of Action

Insulin degludec forms multi-hexameric chains after subcutaneous injection. These chains dissociate slowly, releasing monomers into the bloodstream at a steady rate. The result is a flat, peakless pharmacokinetic profile that reduces overnight hypoglycemia compared to NPH insulin [3].

Approved Doses and Titration

The prescribing information supports starting doses of 10 units once daily in insulin-naive type 2 patients, with titration upward by 2 units every 3 to 5 days to reach a fasting glucose target of 80 to 100 mg/dL [1]. In type 1 diabetes, degludec typically covers 30 to 50 percent of total daily insulin requirements.

Why the Long Half-Life Matters for Supplement Interactions

Because a single dose of Tresiba exerts glucose-lowering action for more than 42 hours, any supplement that also reduces blood glucose will overlap with Tresiba's action window regardless of when either is taken. Timing the supplement away from the injection does not protect against this overlap [2].

What Is Lion's Mane Mushroom?

Lion's mane (Hericium erinaceus) is a culinary and medicinal mushroom used for centuries in East Asian traditional medicine. It is now widely available in the United States as standardized capsules (typically 500 mg to 1,000 mg per dose), liquid extracts, and food products.

Bioactive Compounds

The two principal bioactive compound families are hericenones, found in the fruiting body, and erinacines, found in the mycelium. Both classes stimulate nerve growth factor (NGF) synthesis in vitro and in animal models [4]. Erinacine A, in particular, crosses the blood-brain barrier in rodents and increases NGF in the hippocampus [5].

Why People Use It

Most consumers take lion's mane for cognitive support. A 2023 randomized, double-blind, placebo-controlled trial of 41 adults (ages 18 to 45) found that a single 1.8 g dose of Hericium erinaceus extract improved speed of performance on the Stroop Color-Word Test (P<0.05) within 60 minutes [6]. A separate 2019 trial in older adults with mild cognitive impairment showed significant improvements on the Revised Hasegawa Dementia Scale after 16 weeks of 3 g/day supplementation [7].

Metabolic Effects Worth Noting

Beyond cognition, animal and cell studies show Hericium erinaceus extracts reduce fasting blood glucose, improve insulin sensitivity, and lower HbA1c in streptozotocin-induced diabetic mice [8]. A 2021 review in the Journal of Ethnopharmacology identified alpha-glucosidase inhibition as one probable mechanism, meaning the mushroom slows carbohydrate digestion in a manner similar to acarbose [9].

The Interaction: Pharmacodynamic, Not Pharmacokinetic

The combination of lion's mane and Tresiba produces a pharmacodynamic interaction, meaning both agents act on blood glucose through separate pathways that converge on the same outcome: lower blood sugar. This is distinct from a pharmacokinetic interaction, where one substance changes how the body absorbs, distributes, metabolizes, or excretes the other.

No CYP450 Conflict

Insulin degludec is not metabolized by cytochrome P450 enzymes. It is degraded by the same proteolytic pathways as endogenous insulin [1]. Lion's mane extracts have shown modest CYP3A4 inhibition in cell studies, but because degludec does not use CYP3A4, this finding has no practical relevance to the Tresiba interaction [10].

The Additive Hypoglycemia Mechanism

Tresiba suppresses hepatic glucose output and promotes peripheral glucose uptake by binding insulin receptors. Lion's mane extracts appear to lower glucose through at least three separate mechanisms: alpha-glucosidase inhibition [9], improved pancreatic beta-cell function in animal models [8], and possible GLUT4 translocation enhancement [11]. When these effects layer on top of exogenous insulin from Tresiba, blood glucose can fall lower than either agent would produce alone.

Magnitude of Risk

No human trial has measured how much lion's mane lowers glucose in insulin-treated patients specifically. The animal data suggest meaningful effects: one mouse study found fasting glucose dropped by approximately 30 percent over 28 days of Hericium erinaceus polysaccharide supplementation [8]. Extrapolating that magnitude to a patient on Tresiba is speculative, but the direction of effect is consistent enough to warrant clinical caution [9].

Secondary Concern: Antiplatelet and Anticoagulant Properties

Lion's mane contains compounds that inhibit platelet aggregation in vitro. A study published in the International Journal of Medicinal Mushrooms found that aqueous extracts of Hericium erinaceus reduced ADP-induced platelet aggregation in a concentration-dependent manner [12].

Why This Matters Less for Most Tresiba Users

Insulin degludec itself has no antiplatelet action. The antiplatelet concern becomes clinically relevant only if a patient is also taking aspirin, clopidogrel, warfarin, or a direct oral anticoagulant alongside both Tresiba and lion's mane. In that scenario, bleeding risk increases modestly [12]. Patients on anticoagulation therapy should flag lion's mane use explicitly to their care team.

Renal and Hepatic Considerations

Patients with chronic kidney disease (CKD) stage 3 or higher already face elevated hypoglycemia risk with basal insulin because reduced renal gluconeogenesis blunts their counter-regulatory response [13]. The FDA label for Tresiba notes that renal impairment may increase insulin requirements but simultaneously increases hypoglycemia susceptibility [1]. Adding a glucose-lowering supplement in this population narrows the safety margin further.

Evidence Quality Assessment

The evidence supporting lion's mane's glucose-lowering effect comes almost entirely from animal models and small in vitro studies. No randomized controlled trial has examined Hericium erinaceus specifically in patients using insulin degludec or any other basal insulin. The 2019 human trial by Mori et al. Used 3 g/day in cognitively impaired older adults and did not report glucose outcomes as a primary endpoint [7].

What the Guidelines Say

The American Diabetes Association's Standards of Care in Diabetes 2024 state: "There is no clear evidence of benefit from vitamin or mineral supplementation in people with diabetes who do not have underlying deficiencies" and caution that herbal supplements "may have interactions with medications and should be used with caution" [14]. The Endocrine Society has not issued specific guidance on lion's mane but endorses individualized patient counseling about supplement use before changes to a diabetes regimen [15].

Natural Medicines Database Classification

The Natural Medicines Comprehensive Database rates the combination of blood-glucose-lowering supplements with insulin as carrying a "moderate" interaction risk, defined as a combination that may cause adverse effects and typically warrants monitoring or modification [16]. Lion's mane falls into their "possibly effective" category for blood sugar lowering based on animal and preliminary human data.

Monitoring Protocol If You Are Already Taking Both

If a patient is already combining lion's mane with Tresiba, stopping abruptly is not automatically required. A structured monitoring approach can detect whether the combination is producing clinically meaningful glucose changes.

Step 1: Baseline Glucose Check

Obtain a minimum of 7 days of fasting capillary glucose readings before adding lion's mane (or 7 days of retrospective data if the supplement was added recently). This establishes your individual baseline on Tresiba alone.

Step 2: Increase Monitoring Frequency

Check fasting glucose daily and add a pre-lunch and pre-dinner check for the first 2 weeks after starting lion's mane. Continuous glucose monitor (CGM) users should review time-in-range (TIR) data weekly. A TIR drop below 70 percent or any reading below 70 mg/dL warrants contacting your prescriber [14].

Step 3: Watch for Hypoglycemia Symptoms

Classic symptoms include shakiness, diaphoresis, palpitations, and confusion. Because Tresiba's flat profile reduces symptomatic hypoglycemia, some patients experience "silent lows." CGM alarms set at 80 mg/dL provide an early warning [3].

Step 4: Report to Your Prescriber

Bring your glucose log to your next appointment. If fasting readings have dropped by more than 15 mg/dL from baseline on a stable Tresiba dose, your clinician may reduce the Tresiba dose by 10 to 20 percent while you continue the supplement, or advise stopping the supplement.

Practical Dosing Considerations

Lion's mane supplements vary widely in standardization. Products labeled as "fruiting body extract" differ from "mycelium on grain" products in both erinacine and hericenone content. The clinical trials that did show cognitive benefit used 3 g/day of a standardized fruiting body extract [7]. Many commercial products contain 500 mg to 1,000 mg, meaning consumers would need 3 to 6 capsules daily to match trial doses.

Does Higher Dose Mean Higher Glucose Risk?

The glucose-lowering effects seen in animal models were dose-dependent [8]. A patient taking 500 mg/day likely faces lower additive hypoglycemia risk than one taking 3,000 mg/day. Even lower doses have not been formally tested in insulin-treated humans, so no dose can be declared definitively safe in this context.

Timing Does Not Eliminate the Risk

Because insulin degludec acts over 42-plus hours and lion's mane polysaccharides are absorbed over several hours, there is no practical administration window that fully separates their glucose-lowering actions [2]. Taking lion's mane in the morning and Tresiba at bedtime still results in overlapping pharmacodynamic activity throughout the following day.

Who Should Avoid This Combination Entirely?

Certain patient groups face disproportionate risk and should avoid adding lion's mane to a Tresiba regimen unless under direct specialist supervision.

Patients with type 1 diabetes have no endogenous insulin reserve, so additive glucose lowering carries a steeper hypoglycemia risk than in type 2 diabetes with residual beta-cell function [14]. Patients with hypoglycemia unawareness (defined as loss of autonomic warning symptoms before blood glucose falls below 54 mg/dL) face severe danger because they may not recognize a supplement-augmented low [3]. Patients with CKD stage 3b or higher, as noted above, have reduced gluconeogenic capacity and a blunted glucagon response [13]. Patients already on sulfonylureas or meglitinides in addition to Tresiba face triple additive glucose-lowering from three simultaneous agents.

What the Evidence Does Not Tell Us

The absence of a direct pharmacokinetic interaction does not mean the combination is safe. Several gaps remain in the literature. No trial has measured lion's mane erinacine or hericenone plasma levels in humans to confirm bioavailability at commercial supplement doses [5]. No study has examined whether chronic lion's mane use changes insulin receptor sensitivity in humans with diabetes. The antiplatelet data come from in vitro work, and the clinical relevance in vivo remains undetermined [12].

Ongoing Research

A search of ClinicalTrials.gov as of January 2025 identifies no registered trials examining Hericium erinaceus specifically in insulin-treated patients. The evidence gap itself is clinically relevant: absence of harm data is not evidence of safety [16].

Talking to Your Prescriber: What to Bring

Bring the specific product label (including milligrams per serving and whether it is fruiting body or mycelium), your current Tresiba dose in units, your most recent HbA1c, and your CGM or glucose log from the past 2 weeks. Ask explicitly: "Will this supplement affect my insulin dose?" rather than a general question about safety. A prescriber who can see your actual glucose trend data can make a more informed recommendation than one working from a general interaction database alone [15].